TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer-Reference-Cited by-同舟云学术

TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer

Published:2016-07 Issue:8 Volume:5 Page:e1197459
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Wood Lauren V.,Fojo Antonio,Roberson Brenda D.,Hughes Meghan S. B.,Dahut William,Gulley James L.,Madan Ravi A.,Arlen Philip M.,Sabatino Marianna,Stroncek David F.,Castiello Luciano,Trepel Jane B.,Lee Min-Jung,Parnes Howard L.,Steinberg Seth M.,Terabe Masaki,Wilkerson Julia,Pastan Ira,Berzofsky Jay A.

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.1080/2162402X.2016.1197459

Reference43 articles.

1. American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society; 2014. p.2, p.10; http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/index

2. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

3. EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease

4. High expression of a specific T-cell receptor transcript in epithelial cells of the prostate

5. TARP: A nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer;Human Vaccines & Immunotherapeutics;2024-08-29

2. 557 The epitope-enhanced TARP peptide can induce specific T cells that can recognize wild-type TARP tetramer by either peptide or peptide-pulsed DC vaccination in patients with prostate cancer;Regular and Young Investigator Award Abstracts;2022-11

3. Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment;Cells;2022-09-07

4. In Silico Model Estimates the Clinical Trial Outcome of Cancer Vaccines;Cells;2021-11-05

5. Spherical Nucleic Acid Vaccine Structure Markedly Influences Adaptive Immune Responses of Clinically Utilized Prostate Cancer Targets;Advanced Healthcare Materials;2021-09-08